Cargando…

Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia

Minimal residual disease (MRD) is the most powerful prognostic factor in pediatric acute lymphoblastic leukemia (ALL). Real-time quantitative polymerase chain reaction (RQ-PCR) represents the gold standard for molecular MRD assessment and risk-based stratification of front-line treatment. In the pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Della Starza, Irene, Nunes, Vittorio, Lovisa, Federica, Silvestri, Daniela, Cavalli, Marzia, Garofalo, Andrea, Campeggio, Mimma, De Novi, Lucia Anna, Soscia, Roberta, Oggioni, Carlotta, Mussolin, Lara, Biondi, Andrea, Guarini, Anna, Valsecchi, Maria Grazia, Conter, Valentino, Biffi, Alessandra, Basso, Giuseppe, Foà, Robin, Cazzaniga, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909459/ https://www.ncbi.nlm.nih.gov/pubmed/33655199 http://dx.doi.org/10.1097/HS9.0000000000000543

Ejemplares similares

FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD)
por: Lo Nigro, Luca, et al.
Publicado: (2022)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2023)

Low PKCa expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome
por: Milani, Gloria, et al.
Publicado: (2014)

Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
por: Assanto, Giovanni Manfredi, et al.
Publicado: (2023)

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
por: Del Giudice, Ilaria, et al.
Publicado: (2019)

Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia‐positive acute lymphoblastic leukaemia
por: Ansuinelli, Michela, et al.
Publicado: (2021)

Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network
por: Mantoan, Barbara, et al.
Publicado: (2021)

Patient specific real-time PCR in precision medicine – Validation of IG/TR based MRD assessment in lymphoid leukemia
por: Schilhabel, Anke, et al.
Publicado: (2023)

P374: THROMBOTIC EVENTS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA: EXPERIENCE OF ITALIAN AIEOP CENTERS (2009-2017)
por: Mattera, Raffaele, et al.
Publicado: (2023)

P1232: NON-INVASIVE MINIMAL RESIDUAL DISEASE ANALYSIS BY IMMUNOGLOBULIN GENE REARRANGEMENTS ON CIRCULATING TUMOR DNA PREDICTS THE OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Soscia, Roberta, et al.
Publicado: (2023)

Ruxolitinib as a Novel Therapeutic Option for Poor Prognosis T-LBL Pediatric Patients
por: Veltri, Giulia, et al.
Publicado: (2021)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia
por: Veltri, Giulia, et al.
Publicado: (2022)

Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single‐centre cohort
por: Brivio, Erica, et al.
Publicado: (2022)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice
por: Turner, Rose, et al.
Publicado: (2022)

Sialylation regulates migration in chronic lymphocytic leukemia
por: Natoni, Alessandro, et al.
Publicado: (2023)

RNY4 in Circulating Exosomes of Patients With Pediatric Anaplastic Large Cell Lymphoma: An Active Player?
por: Lovisa, Federica, et al.
Publicado: (2020)

miR-939 acts as tumor suppressor by modulating JUNB transcriptional activity in pediatric anaplastic large cell lymphoma
por: Garbin, Anna, et al.
Publicado: (2020)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

P646: VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
por: Scarfò, Lydia, et al.
Publicado: (2023)

Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
por: Galimberti, Stefania, et al.
Publicado: (2018)

High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia
por: Vendramini, Elena, et al.
Publicado: (2017)

Mutations in cell elongation genes mreB, mrdA and mrdB suppress the shape defect of RodZ-deficient cells
por: Shiomi, Daisuke, et al.
Publicado: (2013)

ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
por: Lovisa, Federica, et al.
Publicado: (2015)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
por: Turcas, Cristina, et al.
Publicado: (2020)

NP-MRD: the Natural Products Magnetic Resonance Database
por: Wishart, David S, et al.
Publicado: (2021)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
por: Askeland, F. B., et al.
Publicado: (2022)

LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients
por: Cazzaniga, Valeria, et al.
Publicado: (2015)

PB1711: DROPLET DIGITAL PCR DETECTION OF THE T315I BCR::ABL1 KD MUTATION IN ADULT PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Cardinali, Deborah, et al.
Publicado: (2023)

MiR-26a-5p as a Reference to Normalize MicroRNA qRT-PCR Levels in Plasma Exosomes of Pediatric Hematological Malignancies
por: Damanti, Carlotta C., et al.
Publicado: (2021)

Technical Report Abstracts: TR-365 to TR-415
Publicado: (1993)

Technical Report Abstracts: TR-335 to TR-364
Publicado: (1993)

Technical Report Abstracts: TR-143 to TR-223
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_jopakk6hi57g4734l08afplu9k